alprazolam has been researched along with Ataxia in 6 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten cardiology chest pain patients without clinical evidence of coronary artery disease and with panic disorder were enrolled in an open label trial of alprazolam." | 9.06 | Alprazolam in the treatment of cardiology patients with atypical chest pain and panic disorder. ( Basha, IM; Beitman, BD; Jayaratna, MA; Russell, BD; Tarr, SK; Trombka, LH, 1988) |
| "In a multicenter placebo-controlled study, the safety, side effects, and patient acceptance of alprazolam for the treatment of panic disorder and agoraphobia were examined." | 9.06 | Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. ( Ballenger, JC; Burrows, GD; DuPont, RL; Noyes, R; Pecknold, JC; Rifkin, A; Rubin, RT; Swinson, RP, 1988) |
| "Ten cardiology chest pain patients without clinical evidence of coronary artery disease and with panic disorder were enrolled in an open label trial of alprazolam." | 5.06 | Alprazolam in the treatment of cardiology patients with atypical chest pain and panic disorder. ( Basha, IM; Beitman, BD; Jayaratna, MA; Russell, BD; Tarr, SK; Trombka, LH, 1988) |
| "In a multicenter placebo-controlled study, the safety, side effects, and patient acceptance of alprazolam for the treatment of panic disorder and agoraphobia were examined." | 5.06 | Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. ( Ballenger, JC; Burrows, GD; DuPont, RL; Noyes, R; Pecknold, JC; Rifkin, A; Rubin, RT; Swinson, RP, 1988) |
| " In contrast, identical treatment did not alter the potency of the benzodiazepine alprazolam to induce ataxia." | 3.67 | Modification of the response to opioid and nonopioid drugs by chronic opioid antagonist treatment. ( Inturrisi, CE; Yoburn, BC, 1988) |
| "Sedation and ataxia were the most common side effects reported, but these effects were mild and transient and did not interfere with treatment outcome." | 2.67 | Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. ( Cohen, LS; Herman, JB; Otto, MW; Pollack, MH; Rosenbaum, JF; Sachs, GS; Spier, SA; Tesar, GE, 1991) |
| "Oral alprazolam tablets were absorbed in adult horses and no clinically relevant adverse events were observed." | 1.42 | Pharmacokinetics and physiologic effects of alprazolam after a single oral dose in healthy mares. ( Alcott, CJ; Coetzee, JF; Davis, JL; Galow-Kersh, NL; Hepworth-Warren, KL; Rice, S; Wong, DM, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ennis, MD | 1 |
| Hoffman, RL | 1 |
| Ghazal, NB | 1 |
| Olson, RM | 1 |
| Knauer, CS | 1 |
| Chio, CL | 1 |
| Hyslop, DK | 1 |
| Campbell, JE | 1 |
| Fitzgerald, LW | 1 |
| Nichols, NF | 1 |
| Svensson, KA | 1 |
| McCall, RB | 1 |
| Haber, CL | 1 |
| Kagey, ML | 1 |
| Dinh, DM | 1 |
| Wong, DM | 1 |
| Davis, JL | 1 |
| Alcott, CJ | 1 |
| Hepworth-Warren, KL | 1 |
| Galow-Kersh, NL | 1 |
| Rice, S | 1 |
| Coetzee, JF | 1 |
| Tesar, GE | 1 |
| Rosenbaum, JF | 1 |
| Pollack, MH | 1 |
| Otto, MW | 1 |
| Sachs, GS | 1 |
| Herman, JB | 1 |
| Cohen, LS | 1 |
| Spier, SA | 1 |
| Beitman, BD | 1 |
| Basha, IM | 1 |
| Trombka, LH | 1 |
| Jayaratna, MA | 1 |
| Russell, BD | 1 |
| Tarr, SK | 1 |
| Noyes, R | 1 |
| DuPont, RL | 1 |
| Pecknold, JC | 1 |
| Rifkin, A | 1 |
| Rubin, RT | 1 |
| Swinson, RP | 1 |
| Ballenger, JC | 1 |
| Burrows, GD | 1 |
| Yoburn, BC | 1 |
| Inturrisi, CE | 1 |
3 trials available for alprazolam and Ataxia
| Article | Year |
|---|---|
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder.
Topics: Adult; Alprazolam; Anxiety Disorders; Ataxia; Clonazepam; Double-Blind Method; Female; Humans; Male; | 1991 |
Alprazolam in the treatment of cardiology patients with atypical chest pain and panic disorder.
Topics: Adult; Alprazolam; Angina Pectoris; Anxiety; Ataxia; Chest Pain; Clinical Trials as Topic; Confusion | 1988 |
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Ataxia; Chemical and Drug Induced Liver Injury; F | 1988 |
3 other studies available for alprazolam and Ataxia
| Article | Year |
|---|---|
2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists.
Topics: Aggression; Animals; Anti-Anxiety Agents; Ataxia; Azepines; Drug Design; Electroshock; Indicators an | 2003 |
Pharmacokinetics and physiologic effects of alprazolam after a single oral dose in healthy mares.
Topics: Administration, Oral; Alprazolam; Animals; Ataxia; Conscious Sedation; Female; Horses; Hypnotics and | 2015 |
Modification of the response to opioid and nonopioid drugs by chronic opioid antagonist treatment.
Topics: Alprazolam; Analgesia; Animals; Ataxia; Cocaine; Drug Implants; Kinetics; Male; Methadone; Mice; Mor | 1988 |